InvestorsObserver
×
News Home

Should Bristol-Myers Squibb Co (BMY) Stock Be in Your Portfolio?

Monday, June 20, 2022 06:36 AM | InvestorsObserver Analysts

Mentioned in this article

Should Bristol-Myers Squibb Co (BMY) Stock Be in Your Portfolio?

Bristol-Myers Squibb Co (BMY) is the highest overall rated company in the Drug Manufacturers - General industry with an overall score of 75. BMY is up 10.38% so far this year after the company closed yesterday at $73.77. The overall score measures the company's performance based-off both short and long term indicators and means that BMY scores better than 75% of the overall market.

Overall Score - 75
BMY has an Overall Score of 75. Find out what this means to you and get the rest of the rankings on BMY!
Bristol-Myers Squibb Co is a strong performer in the Drug Manufacturers - General industry, which has an average overall score of 53. This means that, on average, the stocks in this industry score higher than 53% of the stock market.
To see InvestorsObserver's Sentiment Score for Bristol-Myers Squibb Co click here. BMY has been trading neutral recently. The stock is trading up 0.26% this week following yesterday's decline. BMY has an average analyst ranking of Buy with an average price target of $78.181. Click Here to get the full Stock Report for Bristol-Myers Squibb Co stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App